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http://www.biomedcentral.com/1472-6882/14/283RESEARCH ARTICLE Open AccessEquisetum arvense (common horsetail) modulates
the function of inflammatory immunocompetent
cells
Carsten Gründemann1*, Karin Lengen1, Barbara Sauer1, Manuel Garcia-Käufer1, Martin Zehl2 and Roman Huber1Abstract
Background: In Europe, extracts of Equisetum arvense (common horsetail) have a long tradition in the treatment of
inflammatory disorders. To understand the molecular basis for its use, we investigated the immunomodulatory
capacity of a standardized commercially available common horsetail extract on human primary lymphocyte
function in vitro.
Methods: The standardized extract of Equisetum arvense was phytochemically characterized. Effects on proliferation,
viability and activity of mitogen-activated human lymphocytes were assessed in comparison to cyclosporine A using
annexin V/propidium iodide staining assays and flow cytometry-based surface receptor characterization, respectively.
Intracellular levels of effector molecules (IL-2, IFN-γ and TNF-α) were analyzed with cytokine assays.
Results: T cell proliferation was inhibited dose dependently by the Equisetum extract without induction of apoptosis or
necrosis. This effect was mediated through inhibition of lymphocyte activation, specifically by diminishing CD69 and
IL-2 surface receptor expression and intracellular IL-2 production. Furthermore, treatment with Equisetum arvense
inhibited effector functions, as indicated by reduced production of IFN-γ and TNF-α.
Conclusions: The data indicate that the used extract of Equisetum arvense interferes with the polyfunctionality of
immunocompetent cells thereby providing an anti-inflammatory mode-of-action.
Keywords: Equisetum arvense, Equisetopsida, Horsetail, Inflammation, Lymphocytes, Immunosuppression,
Anthroposophical MedicineBackground
Equisetum arvense (common horsetail, field horsetail, or
giant horsetail) belongs to the Equisetopsida family and is
native to the Arctic and temperate regions of the northern
hemisphere, particularly Europe [1]. Its traditional use as
an herbal remedy is documented in several handbooks of
phytotherapy [2,3] and continues to be popular in comple-
mentary medicine, especially Anthroposophical Medicine
[4]. Among the species of this genus, only Equisetum
arvense “Equiseti herba”) is listed in the German commis-
sion E Monograph (phytotherapy and herbal substances)
of the German Federal Institute for Drugs and Medical
Devices [5] as well as in the European Pharmacopoeia [6].* Correspondence: carsten.gruendemann@uniklinik-freiburg.de
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article, unless otherwise stated.The putative medicinal properties are supported by a
number of studies, which found (I) hepatoprotective [7],
(II) diuretic [8], (III) anti-bacterial [9,10] or (IV) antioxi-
dant effects [11-14]. Furthermore, (V) anti-inflammatory
properties for the treatment of wounds or inflammatory
diseases such as arthritis have been described [15,16].
However, to date, there are no studies on the impact of
Equisetum arvense extracts on lymphocytes involved in
inflammatory immune processes. Lymphocytes are the
body’s second line of defence and T cells are actively re-
cruited to sites of inflammation where they maintain and
activate fibroblasts or bystander dendritic cells and macro-
phages, transforming them into tissue-destructive effector
cells [17]. T lymphocytes are the dominant cells in inflam-
matory immune diseases [18,19], and their proliferation
and mediator release (IFN-γ, TNF-α) are targets for modern
therapies [20]. Immunosuppressants such as glucocorticoidsentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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specifically down-regulate the immune system [20], are
the established treatment of choice. Despite the availability
of effective conventional medications, approximately 60-
90% of patients with inflammatory immune disorders re-
sort to alternative or complementary therapies to avoid
side effects [22]. One such therapy involves use of
Equisetum arvense. Because we were interested in explor-
ing the “active principle”, we phytochemically character-
ized a standardized, commercially available extract of
Equisetum arvense and defined its immunosuppressive
capacity on cell proliferation, activation status and effector
functions using mitogen-activated human lymphocytes.
Methods
Plant material
Equisetum arvense (Equisetopsida), ethanol. Decoctum
(=Equisetum: D1; Weleda AG, Schwäbisch Gmünd,
Germany) was used for the experiments. The extract is
manufactured according to method no. 19f of the German
Homeopathic Pharmacopoeia [23]. The Equisetum arvense
was of European origin and came from wild harvests. The
fresh plant material was kept refrigerated and sent to
Weleda Naturals GmbH, Schwäbisch Gmünd, Germany,
where the identity of the plant material was analyzed by
botanic specialists using macroscopic and microscopic
methods as well as comparison with depositions of speci-
fied botanical reference stocks. The plant material was
dried, homogenized and a decoct was produced by boiling
one part dried plant material with nine parts ethanol for
4 h. The absolute ethanol concentration of the preparation
used was 36 Vol.-%. We used the same concentration of
ethanol for vehicle control experiments and clearly dem-
onstrated that these amounts have no influence on the
behaviour of the cells. After cooling down to room tem-
perature, the decoct was squeezed out mechanically, fil-
tered sterile and filled into 50 mL bottles. Bottles from
sale stocks were sent to our laboratory in Freiburg,
Germany, where the experiments were performed. For
each experiment, a fresh frozen aliquot of the Equisetum
arvense extract was used, and concentrations of 0.05, 0.1,
0.2, 0.4 and 0.8 μg/mL were tested.
Phytochemical analysis of the Equisetum arvense extract
LC-MS analyses were performed on an UltiMate 3000
RSLC-series system (Dionex, Germering, Germany) coupled
to a 3D quadrupole ion trap mass spectrometer equipped
with an orthogonal ESI source (HCT, Bruker Daltonics,
Bremen, Germany). HPLC separation was carried out on
an Acclaim 120 C18, 2.1 × 150 mm, 3 μm column (Dionex)
at 30°C using 0.1% aqueous formic acid and acetonitrile as
mobile phase A and B, respectively. The flow rate was
0.5 mL/min and the following gradient program was used:
5% B (0 min), 5% B (2 min), 11% B (20 min), and 24% B(33 min), followed by a column cleaning and re-
equilibration step. The eluent flow was split at a 1:4 ratio
before the ESI ion source, which was operated as follows:
capillary voltage: +3.5 kV, nebulizer: 26 psi (N2), dry gas
flow: 9 L/min (N2), and dry temperature: 340°C. MS
2, MS3,
and MS4 spectra were obtained in an automated data-
dependent acquisition mode (collision gas: He, isolation
window: 4 Th, fragmentation amplitude: 1.0 V). 2 μL of
the undiluted, centrifuged Equisetum extract were injected.
Finally, two of the tentatively identified components were
confirmed by comparison of the retention times, UV- and
MSn-spectra with the reference compounds isoquercitrin
(Carl Roth, Karlsruhe, Germany) and kaempferol-3-O-
glucoside (Extrasynthese, Genay Cedex, France).
Quantification of the main flavonoid isoquercitrin
(quercetin-3-O-glucoside) in the Equisetum arvense ex-
tract was performed by HPLC-DAD with external stand-
ard calibration, and the total flavonoid content was
determined by a spectrophotometric assay adapted from
the European Pharmacopoeia (Ph. Eur.) Monograph on
Equiseti herba [6] (for details see Additional file 1).
Ethics statement
Patients gave their written consent for giving blood for
scientific research.
All experiments conducted on human material were
approved by the Ethics committee of the University of
Freiburg (55/14).
Preparation and cultivation of human peripheral
lymphocytes
Human peripheral lymphocytes (PBMC) were isolated from
the blood of healthy adult donors obtained from the Blood
Transfusion Centre (Medical Center, University of Freiburg,
Germany). Venous blood was centrifuged on a Lympho-
Prep™ gradient (density: 1.077 g/cm3, 20 min, 500 × g, 20°C;
Progen, Heidelberg, Germany). Cells were washed twice in
medium, and cell viability as well as concentration was de-
termined using the trypan blue exclusion test. Cells were
cultured in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal calf serum (PAA, Pasching, Austria),
2 mM L-glutamine, 100 U/mL penicillin and 100 U/mL
streptomycin (all from Life Technologies, Paisley, UK). The
cells were cultured at 37°C in a humidified incubator with
5% CO2/95% air atmosphere.
Activation and treatment of lymphocytes and T-cells
PBMC (105) were stimulated with phytohemagglutinin-
L (PHA-L; 10 μg/mL; Roche Diagnostics, Mannheim,
Germany) or lipopolysaccharide (LPS; 1 μg/mL; Sigma-
Aldrich, Taufkirchen, Germany) in the presence of control
agents cyclosporine A (CsA; 10 μg/mL obtained by dilu-
tion of Sandimmun® 50 mg/mL, Novartis Pharma GmbH,
Nürnberg, Germany), camptothecin (CPT; 30 μg/mL;
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Roth, Karlsruhe, Germany), or different concentrations of
Equisetum arvense extract. After cultivation, the cells were
assessed in bioassays as described in the text.Cell division tracking using CFSE
PBMC were harvested and washed twice in cold PBS be-
fore they were resuspended in PBS at a concentration of
5 × 106 cells/mL. CFSE (carboxyfluorescein diacetate suc-
cinimidyl ester, 5 mM; Sigma, Taufkirchen, Germany) was
added in 1/1000 dilution and the PBMC were incubated
for 10 min at 37°C. The staining reaction was stopped by
washing twice with complete medium. Afterwards, the cell
division progress was analyzed using flow cytometry.Determination of apoptosis and necrosis using annexin V
and propidium iodide staining
PBMC were cultured in the presence of Equisetum arvense
extract for 24 or 48 h, respectively, and the levels of apop-
tosis and necrosis were determined using Annexin V-FITC
apoptosis detection kit (eBioscience, Frankfurt, Germany
or BD Bioscience, Heidelberg, Germany) according to the
manufacturer’s instructions. After annexin V staining, pro-
pidium iodide solution (PI; eBioscience or BD Bioscience)
was added and the cells were incubated in the dark,
followed by a flow cytometric analysis to determine the
amount of apoptosis and necrosis. We used CPT (100 μM)




Figure 1 Secondary plant metabolites identified in the Equisetum arv
tentatively identified compounds are labelled in the given HPLC chromato
acid isomer (1 and 2), monoferuloyl-tartaric acid isomer (3 and 7), kaempfe
(5), caffeoyl-malic acid (6), kaempferol-3,7-di-O-glucoside (8), kaempferol-3-O
4-coumaric acid (11), kaempferol-3-O-sophoroside (12), caffeic acid methyl est
(15), apigenin-O-glucoside (16), kaempferol-3-O-glucoside (17), dicaffeoyl-tarta
MS-data are provided in Additional file 1: Table S1.CD69 activation marker and IL-2 surface receptor analysis
Cultured cells (24 or 48 h) were washed with PBS
and stained with FITC-labeled anti-human CD69 and
PE-labeled anti-human CD25 mAbs (both eBioscience,
Frankfurt, Germany) for 15 min at 4°C. Next, the cells
were washed twice with PBS, resuspended and transferred
into FACS vials. The expression of CD69 and IL-2 surface
receptor α-chain CD25 was measured by FACS analysis
using a FACSCalibur instrument.
Determination of cytokine production
Cells were treated for 36 h and were restimulated with
PMA (50 ng/mL) and ionomycin (500 ng/mL) (both from
Sigma-Aldrich, Taufkirchen, Germany) for additional 6 h.
Cytokines were measured using intracellular cytokine ana-
lysis. For this purpose, the cells were surface-stained with
anti-human CD8 mAbs (eBioscience), fixed, and perme-
abilized using 4% paraformaldehyde (Sigma-Aldrich) and
Perm/Wash solution (Becton Dickinson, Franklin Lakes,
NJ), followed by staining with PE-conjugated anti-human
IFN-γ mAb or anti-human TNF-α mAb (both from
eBioscience), respectively. Samples were analyzed with a
BD FACSCalibur flow cytometer using BD CellQuest Pro
Software.
Analysis of data
For statistical analysis, data were processed with Microsoft
Excel and IBM SPSS software 20.0. Values are presented
as mean ± SD for the indicated number of independent
experiments. Statistical significance was determined by













ense extract. The herbal preparation was analysed by LC-MS and the
gram showing the DAD response at 340 ± 2 nm: monocaffeoyl-tartaric
rol-3-O-sophoroside-7-O-glucoside (4), quercetin-3,7-di-O-glucoside
-rutinoside-7-O-glucoside (9), quercetin-3-O-sophoroside (10),
er (13), protogenkwanin-4’-O-glucoside (14), quercetin-3-O-glucoside
ric acid (18), and genkwanin-O-glucoside (19). The corresponding
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centration (IC50), a probit regression model for the
dose-response curve was used and data were proc-
essed by ToxRat® software. The asterisks represent
significant differences from controls (*P < 0.05, **P < 0.01,
***P < 0.001).
Results
Phytochemical analysis of the Equisetum arvense extract
There is no clear correlation between traditional use of
this herbal drug and any of its constituent in particular;
however, the Ph. Eur. prescribes a minimum of 0.3% of
total flavonoids expressed as isoquercitrin in the dried
drug [6]. Consequently, we also focused our phytochemical
analysis of the Equisetum arvense extract on flavonoidsFigure 2 Effects of Equisetum arvense on proliferation of primary hum
PBMC (105) were treated with medium, CsA (10 μg/mL) or increasing conc
was assessed by flow cytometry and depicted as representative dot plots (
presented as mean ± SD of five independent experiments and donors. n.d.
represent significant differences from activated untreated controls (CTRL =1and other polar phenolics. First, an HPLC method was de-
veloped to separate the phenolic compounds in the extract
(Figure 1), which were then tentatively identified by LC-
MS with an ESI-ion trap instrument (Additional file 1:
Table S1). Major phenolic constituents of the Equisetum
arvense extract were found to be various mono-, di-, and
triglycosides of kaempferol, quercetin, apigenin, genkwa-
nin and protogenkwanin, as well as some hydroxycin-
namic acid derivatives, most prominently mono- and
dicaffeoyl-tartaric acid. The presence of quercetin-3-O-
glucoside (isoquercitrin) and kaempferol-3-O-glucoside
was confirmed by comparison of the retention times, UV-
and MSn-spectra with reference compounds. Finally, we
determined the total flavonoid content of the Equisetum
arvense extract by a spectrophotometric assay and thean lymphocytes. CFSE-labeled PHA-L (10 μg/mL)-activated human
entrations of Equisetum arvense (0.05-0.8 μg/mL). Cell division analysis
A) for bulk lymphocytes. Results are summarized in (B) and data are
= no detection. The asterisks (*P < 0.05, **P < 0.01, ***P < 0.001)
00%).
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(see Additional file 1).
Equisetum arvense decreased proliferation of mitogen-
activated human lymphocytes
In order to analyze the immunomodulatory activity of
Equisetum arvense, we evaluated the effects on cell growth
and performed proliferation assays with increasing con-
centrations of the Equisetum extract (0.05-0.8 μg/mL)
using CFSE-labeled mitogen (PHA-L)-activated lympho-
cytes (Figure 2). The CFSE dye is inherited from daughter
cells after cell division and each dividing cell loses fluores-
cence intensity without affecting cell viability. The flow cy-
tometry analysis demonstrated that the proliferation of
CFSE+ mitogen-activated lymphocytes was strongly inhib-
ited to levels of no detection in the presence of the positive
control cyclosporine A (CsA) compared to stimulated cells
alone (=100%). The presence of Equisetum concentration-
dependently (0.05 μg/mL: 95% ± 3.2; 0.1 μg/mL: 89% ± 6.6;
0.2 μg/mL: 86% ± 5.1; 0.4 μg/mL: 78% ± 9.8; 0.8 μg/mL:
54% ± 29.8) decreased the proliferative capacity of human
immunocompetent cells compared to stimulated cells
alone (=100%) with an IC50 value of 1.09 μg/mL.
Equisetum arvense-mediated inhibition of proliferation is
not mediated through apoptosis or necrosis induction
In a further step, we aimed to identify the mechanism be-
hind the reduced cell proliferation observed, and quantified
apoptotic and necrotic effects on activated lymphocytes in
the presence of increasing concentrations (0.05-0.8 μg/mL)
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Figure 3 Effects of Equisetum arvense on apoptosis and necrosis indu
72 h and left non-stimulated or PHA-L-activated (10 μg/mL) in the presenc
arvense concentrations (0.05-0.8 μg/mL). Next, the cells were stained with a
CPT (100 μM) and Triton-X100 (0.5%) were used as apoptosis and necrosis
and necrotic (black bars) cells are summarized and presented as mean ± SD
significant differences from non-treated stimulated cells alone (***P < 0.001and necrosis, we used camptothecin and Triton-X 100, re-
spectively. As shown in Figure 3, positive controls signifi-
cantly increased the amount of apoptotic+ (white bars;
156% ± 22) and necrotic+ (black bars; 3962% ± 725) cells.
Equisetum concentrations had no significant influence on
the induction of apoptosis or necrosis compared to stimu-
lated untreated cells alone (=100%).
Equisetum arvense influences cell proliferation capacity
through partial inhibition of lymphocyte activation and
IL-2 biology
A reduced proliferative capacity could be mediated through
inhibition of T cell activation. Figure 4 depicts the respect-
ive experiments and confirms that CsA-treated T-cells ab-
rogate expression of CD69 completely (Figure 4B: 0.5% ±
1.1 and Figure 4C: no detection). Equisetum decreased
the expression of CD69 (0.05 μg/mL: 95% ± 6.2; 0.1 μg/mL:
91% ± 6; 0.2 μg/mL: 86% ± 7.5; 0.4 μg/mL: 78% ± 8.9;
0.8 μg/mL: 71% ± 9.7) at early (Figure 4A and B) but not
at late (Figure 4C) time points compared to controls
(=100%) in a concentration-dependent manner, reveal-
ing that Equisetum exerts its anti-proliferative effect
through inhibition of cell activation.
T cell proliferation is also initiated by activation and
expression of the autocrine growth factor interleukin-2
(IL-2). This promotes interaction with the receptor CD25,
which is up-regulated on the surface of activated T-cells
[24] and by release of endogenous IL-2. Consequently, the
influence of the Equisetum arvense extract on IL-2-
receptor expression and IL-2 secretion was also analyzed
(Figure 5). The results demonstrated that the Equisetum05 0.1 0.2                                           0.4 0.8
- - - - -
- - - - -
+ + + +
*
ction in primary human lymphocytes. 105 PBMC were cultured for
e of medium (CTRL =100%) or in the presence of different Equisetum
nnexin V and propidium iodide and analyzed using flow cytometry.
control, respectively. Results from analysis of apoptotic (white bars)

































31 33 31 31
CD8B
C





CsA - + - - - - -





















Figure 4 Effects of Equisetum arvense on activation of primary human lymphocytes. Stimulated CD8+ T cells were cultured in the presence
of medium, CsA (10 μg/mL) or increasing concentrations (0.05-0.8 μg/mL) of the Equisetum extract. Cells were analyzed for CD69 expression using
FITC-labeled anti-human mAbs. (A) Representative dot plots are shown and data were summarized from experiments at early (B; 24 h) or late
(C; 48 h) time points from five independent experiments and donors. n.d. = no detection. The asterisks (**P < 0.01, ***P < 0.001) represent
significant differences from activated untreated controls (CTRL =100%).
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Figure 5 Effects of Equisetum arvense on IL-2 biology of primary human lymphocytes. Medium-, CsA or Equisetum-treated activated (PHA-L:
10 μg/mL) lymphocytes were surface-stained with anti-human CD25 mAbs and were analyzed at early (A; 24 h) or at late (B; 48 h) time points.
For IL-2 production analysis, cells were treated for 36 h and were restimulated with PMA (50 ng/mL) and ionomycin (500 ng/mL) for additional
6 h followed by surface-staining with anti-human CD8 mAbs and intracellular cytokine assay with PE-conjugated anti-human IFN-γ mAbs or
anti-human TNF-α mAbs (C). Cells were analyzed using flow cytometry. Data were expressed and summarized as mean ± SD of five independent
experiments and donors. The asterisks (*P < 0.05, **P < 0.01, ***P < 0.001) represent significant differences from activated untreated controls
(CTRL =100%).
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the IL-2 receptor at late time points at high (0.8 μg/mL:
90% ± 14) concentrations only (Figure 5B). It also in-
hibits production of IL-2 (Figure 5C; 0.4 μg/mL: 70% ±
14; 0.8 μg/mL: 55% ± 35) compared to controls (=100%).
These data indicate that Equisetum arvense reduces
proliferation of immunocompetent cells by inhibiting
cell activation and IL-2 biology at more than one site.Equisetum arvense slightly affects effector function of
activated human lymphocytes
Consequently, it was of interest whether the Equisetum
extract under investigation only inhibits proliferation of
lymphocytes or also affects lymphocyte polyfunctionality,
which would be directly related to changes in the produc-
tion of interferon-gamma (IFN-γ) and tumor necrosis
factor-alpha (TNF-α). The production of both mediators
Gründemann et al. BMC Complementary and Alternative Medicine 2014, 14:283 Page 8 of 10
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lyzed using a flow cytometry-based intracellular cytokine
approach (Figure 6). The results showed a slight inhibition
of the IFN-γ- (Figure 6A; 0.4 μg/mL: 63% ± 26; 0.8 μg/mL:
70% ± 18) as well as TNF-α- (Figure 6B; 0.8 μg/mL: 82% ±
22) production of activated T cells at high Equisetum con-
centrations, whereby the presence of CsA reduced secre-
tion of these parameters to undetectable levels.
Discussion
Extracts of Equisetum arvense (common horsetail) have a
long tradition in the treatment of inflammatory disorders,
for which reason we were interested in clarifying whether
there is a rational basis for its use. To this end, we charac-
terized a standardized common horsetail extract in cell-
based assays using activated immunocompetent cells.
We found a concentration-dependent inhibition of
mitogen-activated lymphocyte proliferation with an IC50
value of 1.09 μg/mL. Furthermore, our data indicate that




























































Figure 6 Effects of Equisetum arvense on effector function of primary
(105) were treated with medium, CsA (10 μg/mL) or increasing concentratio
followed by a restimulation period with PMA (50 ng/mL) and ionomycin (5
anti-human CD8 mAbs and intracellular cytokines were detected using PE-
detection. The asterisks (*P < 0.05, **P < 0.01, ***P < 0.001) represent significarvense extract was not mediated by apoptosis and necro-
sis. Immunosuppressive effects of Equisetum arvense have
also been observed by other groups, however, their investi-
gations were only done with human cancer cell lines
[11,25]. T-cell proliferation is a process initiated by ligation
of the T-cell receptor to antigens that triggers a complex
T-cell receptor signalling pathway. During this process,
the human transmembrane C-Type lectin protein CD69 is
expressed on the surface of activated T-cells [24]. CD69
is an early activation marker that is expressed at high
amounts immediately after activation, and gene as well
protein expression of this marker rapidly decreases 24 h
after stimulation. We found a decrease in the activation
status of stimulated T-cells after stimulation, whereby
the effects of Equisetum are smaller than that of CsA. T-
lymphocyte proliferation is further initiated by activation
and expression of the autocrine growth factor interleukin-
2 (IL-2), which promotes interaction with the receptor
CD25 that is up-regulated on the surface of activated
T-cells [24] and by release of endogenous IL-2. The***
*
+ + + +
- - - -
0.1 0.2                                           0.4   0.8
human lymphocytes. Activated (PHA-L; 10 μg/mL) human PBMC
ns of Equisetum arvense (0.05-0.8 μg/mL) and were cultured for 36 h
00 ng/mL) for additional 6 h. Next, cells were surface-stained with
conjugated anti-human IFN-γ or anti-human TNF-α mAbs. n.d. = no
ant differences from activated untreated controls (CTRL =100%).
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in the presence of Equisetum. Over time, however, inhib-
ition was smaller than that of CsA, which specifically re-
duces the early activation state of lymphocytes due to
suppression of the IL-2 receptor [26,27]. The data further
demonstrate that Equisetum reduces IL-2 cytokine pro-
duction. Because IL-2 is pivotal for lymphocyte prolifera-
tion, inhibition of its production may at least partially
explain the immunosuppressive effects of Equisetum in
these experiments. In addition, a slight inhibition of IFN-
γ- and TNF-α-production of activated T cells could be
shown. Thus, we can conclude that the horsetail extract
interferes with T-cell polyfunctionality, which results in di-
minished proliferation of immunocompetent cells.
The stems of Equisetum arvense contain high amounts of
minerals, in particular silicic acid and silicates (5-8%), po-
tassium and calcium, various flavonoids (0.2-0.9%) and
phenolic acids, the phenolic petrosins onitin and oniti-
9-O-glucoside, equisetumpyrone (only in the very early
developmental stages), triterpenoids and phytosterols. They
also contain low amounts of essential oil, the main cons-
tituents being hexahydrofarnesyl acetone, cis-geranyl acet-
one, thymol, and trans-phytol as well as a few other
compounds [28,29]. Especially, the considerable amounts of
polyphenols and several compounds of this diverse group
of phytochemicals have attracted interest in the past due to
their presumptive physiological activities. However, there is
no clear correlation between the traditional use of this
herbal drug and any constituents in particular. The Ph. Eur.
requires a minimum of 0.3% of total flavonoids expressed
as isoquercitrin in the dried drug [6]. Consequently, we
focused our phytochemical analysis of the investigated
Equisetum arvense extract on flavonoids and other polar
phenolics. The phenolic pattern is largely in agreement with
a previous study on the variation of phenolics in different
species of the genus Equisetum subgenus Equisetum, and is
characteristic for the European chemotype of E. arvense
[29,30]. The main difference found in the qualitative com-
position to the study by Veit et al. [29] is that we did not
detect significant amounts of malonylated flavonoid glyco-
sides. Several of the numerous known components of the
characterized Equisetum extract have been reported to
possess anti-inflammatory activity [31-34]. We know from
the literature, that given orally polyphenols (specifically
flavanols, flavonols, flavanones, flavones) are absorbed by
enterocytes and do not reach circulation [35]. Systemic
effects of orally applied polyphenols therefore cannot be
expected. Rather, topical treatment of the skin or mucosa
would be more realistic to reach concentrations of Equi-
setum comparable to our in vitro experiments.
Conclusions
The presented data indicate that the Equisetum arvense ex-
tract used interferes polyfunctionally with immunocompetentcells, thereby providing a potential mechanism that ex-
plains its traditional use in the treatment of inflammatory
disorders. However, further studies should be conducted
to prove its clinical potency.
Additional file
Additional file 1: Quantification of isoquercitrin and total
flavonoids in the Equisetum arvense extract.
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